Quanterix Corp
$ 3.10
2.31%
12 Jun - close price
- Market Cap 146,029,000 USD
- Current Price $ 3.10
- High / Low $ 3.17 / 2.98
- Stock P/E N/A
- Book Value 6.00
- EPS -2.35
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.13 %
- ROE -0.35 %
- 52 Week High 8.77
- 52 Week Low 2.40
About
Quanterix Corporation, a life sciences company, develops and markets digital immunoassay platforms that advance precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the regions from Asia Pacific. The company is headquartered in Billerica, Massachusetts.
Analyst Target Price
$4.33
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-06 | 2026-03-02 | 2025-11-10 | 2025-08-07 | 2025-05-12 | 2025-03-17 | 2024-11-11 | 2024-08-08 | 2024-05-07 | 2024-02-29 | 2023-11-06 | 2023-08-07 |
| Reported EPS | 0.16 | -0.47 | -0.73 | -0.77 | -0.53 | -0.3 | -0.22 | -0.25 | -0.26 | -0.33 | -0.21 | -0.13 |
| Estimated EPS | -0.62 | -0.4322 | -0.53 | -0.41 | -0.43 | -0.254 | -0.23 | -0.26 | -0.31 | -0.32 | -0.4 | -0.41 |
| Surprise | 0.78 | -0.0378 | -0.2 | -0.36 | -0.1 | -0.046 | 0.01 | 0.01 | 0.05 | -0.01 | 0.19 | 0.28 |
| Surprise Percentage | 125.8065% | -8.746% | -37.7358% | -87.8049% | -23.2558% | -18.1102% | 4.3478% | 3.8462% | 16.129% | -3.125% | 47.5% | 68.2927% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: QTRX
2026-06-12 22:09:43
Quanterix CCO Benjamin Meadows recently purchased 3,500 shares of company stock for $9,695, indicating a potential undervalued stock according to InvestingPro analysis despite a 60% decline in the past six months. This transaction follows the company's Q1 2026 earnings report, which exceeded EPS expectations but missed revenue targets, and recent leadership changes including a new CFO and a Senior VP for Diagnostics. These developments aim to strengthen Quanterix's leadership and strategic focus.
2026-06-12 21:08:54
Quanterix CCO Benjamin Meadows has filed a Form 3, disclosing his initial equity holdings in the company. These holdings include 76,234 stock options with an exercise price of $5.88, 22,959 restricted stock units granted on October 6, 2025, and an additional 70,223 restricted stock units and 70,223 performance stock units granted on February 15, 2026. This filing outlines the vesting schedules for these equity awards, linking them to continued service and performance conditions.
2026-06-12 21:08:54
Quanterix's Chief Commercial Officer, Benjamin Meadows, recently purchased 3,500 shares of company common stock in an open-market transaction. The shares were bought at a price of $2.77 per share on May 12, 2026, increasing his direct holdings to 3,500 shares. This transaction, detailed in a Form 4 SEC filing, indicates an insider purchase valued at $9,695.
2026-06-10 20:12:33
Quanterix (QTRX) has named Jason Faessler as its new Chief Financial Officer and Treasurer, effective June 22, 2026, to strengthen its financial leadership for strategic growth initiatives. Faessler brings extensive experience from previous finance roles and will be crucial in capital planning and operational finance. His compensation package includes a significant annual salary, a sign-on bonus, performance bonuses, and long-term equity, reflecting the company's commitment to securing experienced financial guidance.
2026-06-09 19:04:56
This article provides a transcript of Quanterix Corporation's presentation at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. The content includes an introduction by an analyst and the beginning of a presenter's speech, indicating that the full transcript is available to subscribers. Also included are recent news updates about Quanterix, such as executive appointments and financial results.
2026-06-09 17:38:56
Quanterix Corporation (Nasdaq: QTRX) has appointed Jason Faessler as its new Chief Financial Officer, effective June 22. Faessler brings extensive financial leadership experience from the life sciences and healthcare sectors, including roles at Bruker Corporation and PAREXEL. His appointment is expected to strengthen Quanterix's executive leadership as the company advances its growth strategy in research, diagnostics, and precision medicine, particularly following its acquisition of Akoya Biosciences to expand spatial biology capabilities.
